沙利度胺联合CHOP化疗方案治疗非霍奇金淋巴瘤患者的效果

Effects of Thalidomide combined with CHOP chemotherapy in treatment of patients with non-Hodgkin’s lymphoma

目的:观察沙利度胺联合CHOP化疗方案治疗非霍奇金淋巴瘤(NHL)患者的效果。方法:选取2020年2月至2023年2月该院收治的78例NHL患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各39例。对照组采用CHOP化疗方案治疗,研究组在对照组基础上联合沙利度胺治疗。比较两组临床疗效,治疗前后血清学指标[乳酸脱氢酶(LDH)、血管内皮生长因子(VEGF)、β2微球蛋白(β2-MG)]水平、免疫球蛋白[免疫球蛋白M(IgM)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)]水平、血清可溶性程序性死亡配体-1(sPD-L1)和可溶性CD30(sCD30)水平,以及不良反应发生率。结果:研究组客观缓解率(ORR)为74.36%,高于对照组的51.28%,差异有统计学意义(P<0.05);治疗后,研究组LDH、VEGF、β2-MG、sPD-L1、sCD30水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组IgM、IgA、IgG水平均高于对照组,差异有统计学意义(P<0.05);两组消化道反应、骨髓抑制、肝脏损害、血细胞减少等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:沙利度胺联合CHOP化疗方案治疗NHL患者可提高ORR和免疫球蛋白水平,降低血清学指标水平和sPD-L1、sCD30水平,效果优于单纯CHOP化疗方案治疗。

Objective:To observe effects of Thalidomide combined with CHOP chemotherapy in treatment of patients with non-Hodgkin’s lymphoma(NHL).Methods:A prospective study was conducted on 78 NHL patients admitted to the hospital from February 2020 to February 2023.They were divided into study group and control group according to the random number table method,39 cases in each.The control group was treated with CHOP chemotherapy,while the study group was treated with Thalidomide on the basis of that of the control group.The clinical efficacy,the serological indexes[lactate dehydrogenase(LDH),vascular endothelial growth factor(VEGF),β2-microglobulin(β2-MG)]levels,the immunoglobulin[immunoglobulin M(IgM),immunoglobulin A(IgA),immunoglobulin G(IgG)]levels,the serum soluble programmed death ligand-1(sPD-L1)and soluble CD30(sCD30)levels before and after the treatment,and incidence of adverse reactions were compared between the two groups.Results:The objective remission rate(ORR)of the study group was 74.36%,which was higher than 51.28%of the control group,the difference was statistically significant(P<0.05).After the treatment,the levels of LDH,VEGF,β2-MG,sPD-L1 and sCD30 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IgM,IgA and IgG in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as gastrointestinal reactions,bone marrow suppression,liver damage,and cytopenia between the two groups(P>0.05).Conclusions:Thalidomide combined with CHOP chemotherapy in the treatment of the NHL patients can improve the ORR and the immunoglobulin levels and reduce the serological index levels,the sPD-L1 levels and the sCD30 levels.Moreover,it is superior to single CHOP chemotherapy.